Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes.
The aim of this trial is to assess the benefits and possible harms of two regimens of antenatal corticosteroids, dexamethasone phosphate 4x6mg IM q12h and betamethasone phosphate 4x2mg IM q12h, compared to placebo, when given to pregnant women in the late preterm period (gestation age of 34+0 to 36+5 weeks) when they are at risk of preterm birth.
1 Jan 2022–31 Dec 2025
Bill & Melinda Gates Foundation
For any general enquiries relating to this project, please contact:
Principal Research Fellow
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
